AstraZeneca, Merck finally grab a green light for #RareDisease med Koselugo. With Koselugo finally getting approved for NF1, will AZ’s acquisition from Array BioPharma be worth the investment? $AZN $MRK https://t.co/wsEQFWaor0 https://t.co/0Zba0XHN3v